Biotechnology News and Research

RSS

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.

From Baxter International Inc. 11 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

INVISTA joins CPI for development of new technologies to enable gas-fermentation-based processes

INVISTA and The Centre for Process Innovation (CPI) announce a collaboration for the development of new technologies to enable gas-fermentation-based processes for the production of industrial chemicals.

10 Dec 2013

Computational predictive toxicology services available in SafeBridge Consultants

SafeBridge Consultants, Inc., a division of Trinity Consultants, Inc., Dallas, TX, with offices in Mountain View, CA, New York, NY, and Liverpool, UK, announces the availability of computational predictive toxicology services to the biopharmaceutical and chemical industry.

10 Dec 2013

Scientists devise method to measure forces in 3D tissues, living embryos

As embryonic tissue develops, cells push and pull on each other, and they must do so correctly for the tissue to develop properly. Now scientists at Harvard University have devised the first method to measure these forces in three-dimensional (3D) tissues and living embryos.

10 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial.

9 Dec 2013

UC Santa Barbara extends research contract with Army Research Laboratory

UC Santa Barbara's Institute for Collaborative Biotechnologies has received an extension of its contract with the U.S. Army Research Laboratory-Army Research Office, providing an additional $48 million over three years to support research that is inspired by biological systems. The continuation in ICB funding speaks to the success of a decade of fundamental research in the areas of biotechnology, chemistry, engineering, physics, materials science, computer science, neuroscience and medicine.

9 Dec 2013

Downregulation of caveolin-1 contributes to synaptic plasticity deficit in hippocampus of aged rats

Caveolin-1 may be a new target for interfering with age-dependent decline in synaptic plasticity. To explore the relationship between synaptic plasticity in the aging process and changes in learning and memory, Dr. Yang Liu and coworkers from the First Affiliated Hospital, Dalian Medical University, China examined synaptophysin expression in the hippocampus, cortex and cerebellum of rats at different ages, and analyzed the association between synaptophysin expression and cognition and behaviors.

9 Dec 2013

Saudi Human Genome Program to study genetic basis of all disease in the Kingdom

The King Abdulaziz City for Science and Technology, Saudi Arabia's national funding agency, and Life Technologies Corporation today announce The Saudi Human Genome Program – a national research project to study the genetic basis of all disease in the Kingdom and throughout the Middle East and use the findings to offer the ultimate personal care in Saudi Arabia.

8 Dec 2013

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

6 Dec 2013

Tel Aviv University says caffeine and alcohol can change part of DNA linked to aging, cancer

Coffee and beer are polar opposites in the beverage world. Coffee picks you up, and beer winds you down.

6 Dec 2013

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.

5 Dec 2013

Laboratoire Cerba launches noninvasive prenatal test in multiple countries

Sequenom, Inc., a life sciences company providing innovative testing and genetic analysis solutions, announced that Laboratoire Cerba has launched its validated noninvasive prenatal test to health care providers and their patients in France, Belgium, Luxembourg and portions of the Middle East and Africa.

4 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Biotechnology News and Research

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

INVISTA joins CPI for development of new technologies to enable gas-fermentation-based processes

Computational predictive toxicology services available in SafeBridge Consultants

Scientists devise method to measure forces in 3D tissues, living embryos

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

UC Santa Barbara extends research contract with Army Research Laboratory

Downregulation of caveolin-1 contributes to synaptic plasticity deficit in hippocampus of aged rats

Saudi Human Genome Program to study genetic basis of all disease in the Kingdom

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

Tel Aviv University says caffeine and alcohol can change part of DNA linked to aging, cancer

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Laboratoire Cerba launches noninvasive prenatal test in multiple countries

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News